Libertyville, IL, United States of America

Eric Allen Schmitt

USPTO Granted Patents = 17 (Patent Applications = 15)

CIPO Patents = 2 (Patent Applications = 9)

EPO Patents = 3 (Patent Applications = 7)

Average Co-Inventor Count = 6.6

ph-index = 5

Forward Citations = 84(Granted Patents)

Company Filing History:

Abbott Laboratories Corporation

patents

2 out of 2,198

Smithkline Beecham Corporation

Years Active: 2002-2019

Loading Chart...

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10213433 - Solid dispersions containing an apoptosis-inducing agent (2019-02-26),

2. 10105365 - Solid antiviral dosage forms (2018-10-23),

3. 9744170 - Solid antiviral dosage forms (2017-08-29),

4. 9333204 - Solid antiviral dosage forms (2016-05-10),

5. 9248193 - Formulations of phenyl uracil compounds (2016-02-02),

6. 9163052 - Crystalline forms of an antiviral benzimidazole compound (2015-10-20),

7. 9107830 - Inhibitors of crystallization in a solid dispersion (2015-08-18),

8. 8927009 - ABT-263 capsule (2015-01-06),

9. 8728516 - Stabilized lipid formulation of apoptosis promoter (2014-05-20),

10. 8557995 - Solid dispersions containing kinase inhibitors (2013-10-15),

11. 7714123 - Crystalline forms of an antiviral benzimidazole compound (2010-05-11),

12. 7449584 - N-(2((4-Hydroxyphenyl)amino)pyridin-3-yl)-4-methoxybenzenesulfonamide Crystalline Form 1 (2008-11-11),

13. 7446206 - N-((2Z)-2-((4-hydroxyphenyl) amino)-1,2-dihydro-3-pyridinyl)-4-methoxybenzenesulfonamide crystalline form 2 (2008-11-04),

14. 7364752 - Solid dispersion pharamaceutical formulations (2008-04-29),

15. 7297683 - Crystalline forms of an antiviral benzimidazole compound (2007-11-20),

Title: The Innovative Contributions of Eric Allen Schmitt

Introduction

Eric Allen Schmitt is a notable inventor based in Libertyville, IL (US), recognized for his significant contributions to the field of pharmaceuticals. With a total of 17 patents to his name, Schmitt has made strides in developing innovative solutions for medical treatments, particularly in the areas of cancer and antiviral infections.

Latest Patents

Among his latest patents, Schmitt has developed a solid dispersion containing an apoptosis-inducing agent. This pro-apoptotic solid dispersion comprises a Bcl-2 family protein inhibitory compound in essentially non-crystalline form, dispersed in a solid matrix that includes a pharmaceutically acceptable water-soluble polymeric carrier and a surfactant. The process for preparing this solid dispersion involves dissolving the compound, the polymeric carrier, and the surfactant in a suitable solvent, followed by the removal of the solvent to create a solid matrix. This innovative solid dispersion is suitable for oral administration to treat diseases characterized by the overexpression of anti-apoptotic Bcl-2 family proteins, such as cancer. Additionally, Schmitt has worked on solid antiviral dosage forms that comprise antiviral compounds and methods for using these dosage forms to treat antiviral infections.

Career Highlights

Throughout his career, Schmitt has been associated with prominent companies such as AbbVie Inc. and Abbott Laboratories Corporation. His work in these organizations has allowed him to contribute to groundbreaking research and development in the pharmaceutical industry.

Collaborations

Schmitt has collaborated with notable professionals in his field, including Jonathan Mark Miller and Rajeev Gokhale. These collaborations have further enhanced his innovative capabilities and have led to the development of impactful medical solutions.

Conclusion

Eric Allen Schmitt's contributions to the field of pharmaceuticals through his patents and collaborations highlight his role as a significant inventor. His work continues to influence the development of treatments for critical health issues, showcasing the importance of innovation in medicine.

This text is generated by artificial intelligence and may not be accurate.